An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy. by Goker-Alpan, Ozlem et al.
UC Davis
UC Davis Previously Published Works
Title
An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with 
Fabry disease who are naïve to enzyme replacement therapy.
Permalink
https://escholarship.org/uc/item/9pd8w5wg
Authors
Goker-Alpan, Ozlem
Longo, Nicola
McDonald, Marie
et al.
Publication Date
2016
DOI
10.2147/dddt.s102761
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
© 2016 Goker-Alpan et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Drug Design, Development and Therapy 2016:10 1771–1781
Drug Design, Development and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1771
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/DDDT.S102761
an open-label clinical trial of agalsidase alfa enzyme 
replacement therapy in children with Fabry disease 
who are naïve to enzyme replacement therapy
Ozlem goker-alpan1
nicola longo2
Marie McDonald3
suma P shankar4,5
raphael schiffmann6
Peter chang7
Yinghua shen7
arian Pano7
1lysosomal Disorders Unit, Fairfax, 
Va, 2University of Utah, salt lake city, 
UT, 3Department of Pediatrics, Duke 
University, Durham, nc, 4Department 
of Ophthalmology, 5Department of 
human genetics, emory University 
school of Medicine, atlanta, ga, 
6institute of Metabolic Disease, Baylor 
research institute, Dallas, TX, 7shire, 
lexington, Ma, Usa
Background: Following a drug manufacturing process change, safety/efficacy of agalsidase 
alfa were evaluated in enzyme replacement therapy (ERT)-naïve children with Fabry disease.
Methods: In an open-label, multicenter, Phase II study (HGT-REP-084; Shire), 14 children 
aged $7 years received 0.2 mg/kg agalsidase alfa every other week for 55 weeks. Primary 
endpoints: safety, changes in autonomic function (2-hour Holter monitoring). Secondary 
endpoints: estimated glomerular filtration rate, left ventricular mass index (LVMI), midwall 
fractional shortening, pharmacodynamic parameters, and patient-reported quality-of-life.
Results: Among five boys (median 10.2 [range 6.7, 14.4] years) and nine girls (14.8 [10.1, 15.9] 
years), eight patients experienced infusion-related adverse events (vomiting, n=4; nausea, n=3; 
dyspnea, n=3; chest discomfort, n=2; chills, n=2; dizziness, n=2; headache, n=2). One of these 
had several hypersensitivity episodes. However, no patient discontinued for safety reasons and 
no serious adverse events occurred. One boy developed immunoglobulin G (IgG) and neutral-
izing antidrug antibodies. Overall, no deterioration in cardiac function was observed in seven 
patients with low/abnormal SDNN (standard deviation of all filtered RR intervals; ,100 ms) 
and no left ventricular hypertrophy: mean (SD) baseline SDNN, 81.6 (20.9) ms; mean (95% 
confidence interval [CI]) change from baseline to week 55, 17.4 (2.9, 31.9) ms. Changes in 
SDNN correlated with changes in LVMI (r=−0.975). No change occurred in secondary efficacy 
endpoints: mean (95% CI) change from baseline at week 55 in LVMI, 0.16 (−3.3, 3.7) g/m2.7; 
midwall fractional shortening, −0.62% (−2.7%, 1.5%); estimated glomerular filtration rate, 0.15 
(−11.4, 11.7) mL/min/1.73 m2; urine protein, −1.8 (−6.0, 2.4) mg/dL; urine microalbumin, 0.6 
(−0.5, 1.7) mg/dL; plasma globotriaosylceramide (Gb
3
), −5.71 (−10.8, −0.6) nmol/mL; urinary 
Gb
3
, −1,403.3 (−3,714.0, 907.4) nmol/g creatinine, or clinical quality-of-life outcomes.
Conclusion: Fifty-five weeks’ agalsidase alfa ERT at 0.2 mg/kg every other week was 
well tolerated. Disease progression may be slowed when ERT is started prior to major organ 
dysfunction.
Trial registration: https://ClinicalTrials.gov identifier NCT01363492.
Keywords: agalsidase alfa, efficacy, enzyme replacement therapy, Fabry disease, pediatric 
study, safety
Introduction
Fabry disease (FD) is an X-linked, glycosphingolipid storage disorder caused by 
deficient activity of the lysosomal enzyme alpha-galactosidase A, resulting from altera-
tions in the alpha-galactosidase A gene.1 Alpha-galactosidase A deficiency is thought 
to cause progressive accumulation of globotriaosylceramide (Gb
3
) in the lysosomes of 
vascular endothelial cells of multiple organ systems: kidneys, heart, skin, and brain, 
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leading to significant morbidity2 and premature death.3 
More recently, the deacylated Gb
3
 globotriaosylsphingosine 
(lysoGb
3
) was also shown to occur at high concentrations in 
the plasma of patients with FD and was hypothesized to play 
a role in the pathogenesis of this disorder.4
The clinical onset of FD manifestations usually occurs 
during late childhood and adolescence, and signs and 
symptoms become more severe with increasing age. It was 
originally thought that females experienced a milder form 
of FD,5 but studies have shown that the disease can be just 
as severe as in males.6,7 Furthermore, age at both symptom 
onset and diagnosis has been found to be more variable 
in females, although may occur later than in males.8,9 The 
clinical phenotype of FD in pediatric patients has been 
described in several studies. Similar to studies in adults, it 
shows a higher incidence and an earlier onset of symptoms 
in male than in female patients. These include neurological 
manifestations (acroparesthesias, chronic neuropathic pain, 
hypo-anhidrosis, tinnitus, and hearing loss), gastrointestinal 
symptoms (abdominal pain and diarrhea), angiokeratomas, 
and ocular abnormalities (cornea verticillata, tortuous reti-
nal vessels, and subcapsular cataracts). In addition, signs of 
major organ damage (microalbuminuria or proteinuria, 
urinary hyperfiltration, left ventricular hypertrophy [LVH], 
and stroke) are occasionally encountered in children with 
FD,10–12 although these generally manifest in adulthood. Some 
of the cardiac manifestations of FD observed in childhood 
include mitral valve prolapse, alterations in left ventricular 
geometry, and increased left ventricular mass (LVM) inde-
pendently in both boys and girls.13
Enzyme replacement therapy (ERT) in children has the 
potential to halt disease progression and reverse some of the 
signs and symptoms. Previous studies determined an initial 
safety profile and efficacy follow-up of agalsidase alfa treat-
ment in children with FD.14–17 An initial beneficial response 
of cardiac autonomic innervation and an improvement in 
heart rate variability (HRV) were previously reported with 
agalsidase alfa therapy.16
The method of manufacturing agalsidase alfa has changed 
from a roller bottle to a bioreactor process. Per International 
Conference on Harmonisation (ICH) Q5E guidance,18 the 
results of in vitro and in vivo analyses showed that agalsi-
dase alfa manufactured using both processes is comparable 
in terms of pharmacokinetics, biodistribution, and pharma-
codynamics. This study using agalsidase alfa manufactured 
via the bioreactor process was performed as a comparison 
to similar studies that used agalsidase alfa produced via the 
roller bottle process16,17 to satisfy a specific obligation to the 
European Medicines Agency to provide additional clini-
cal data. The primary objective was to assess the safety of 
agalsidase alfa (0.2 mg/kg body weight every other week) in 
ERT-naïve children with FD. Efficacy and pharmacodynamic 
parameters are also reported.
Methods
study design
In an open-label, multicenter clinical trial, treatment-naïve 
children (aged 7 to ,18 years) with FD received agalsidase 
alfa from May 2011 to April 2013 (ClinicalTrials.gov identi-
fier NCT01363492). FD diagnosis was confirmed by measur-
ing alpha-galactosidase A activity in serum, leukocytes, or 
fibroblasts in male subjects, or through molecular analysis 
of alpha-galactosidase A gene mutations in both females and 
males. Written informed consent/assent was required from 
each patient, their parent(s), or legal guardian(s) before par-
ticipation. The study complies with Good Clinical Practice 
guidelines and the Declaration of Helsinki, and was reviewed 
by local institutional review boards. The study procedures 
were approved and conducted according to Western Insti-
tutional Review Board, Olympia, WA; Emory University 
Institutional Review Board, Atlanta, GA; The University 
of Utah Institutional Review Board, Salt Lake City, UT; 
Copernicus Group IRB, Durham, NC; and Baylor Research 
Institute Office of Research Subject Protection, Dallas, TX 
clinical protocol.
Agalsidase alfa, at 0.2 mg/kg body weight intravenously 
(IV), was infused over 40 minutes (±10 minutes) every other 
week for up to 55 weeks.19 Infusions and clinical assessments, 
including height and weight measurements, were performed 
at the clinical sites for at least 13 weeks, with the option for 
home infusions after this period, dependent on investigator 
consent. A post hoc analysis calculated Z-scores for height 
and body mass index (BMI) using World Health Organization 
standards.20
safety evaluation
Safety was a primary endpoint and assessments included 
monitoring adverse events (AEs), measuring anti-agalsidase 
alfa antibody formation, clinical laboratory testing, physical 
examinations, and 12-lead electrocardiograms (ECGs). All 
AEs that occurred from the time of enrollment to 30 (±7) 
days after the last treatment dose were recorded by the 
investigator in terms of potential relationship to agalsidase 
alfa and severity. Mild and moderate AEs were defined 
as causing none or some limitations to normal activities, 
respectively, and severe AEs as causing inability to carry 
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out usual activities. Any AEs that occurred on or after the 
first agalsidase alfa infusion and within 37 days of the final 
infusion were regarded as treatment-emergent AEs. Any 
AEs that occurred within 12 hours after infusion started and 
were deemed possibly or probably related to agalsidase alfa 
were regarded as infusion-related AEs. Any AE that was life-
threatening, required or prolonged hospitalization, or resulted 
in persistent disability was recorded as a serious AE.
Anti-agalsidase alfa antibody testing was performed 
at the Shire Bioanalytical and Biomarker Development 
laboratory using a tiered approach. Briefly, all samples were 
first screened using enzyme-linked immunosorbent assays 
(ELISAs) for the presence of anti-agalsidase alfa immuno-
globulin G, A, M, E (IgG, IgA, IgM, and IgE) isotype anti-
bodies. When a signal of any sample met the IgG, IgA, IgM, 
or IgE positive cut-point criteria, the same isotype-specific 
ELISA was performed again to confirm the presence of 
antibodies. Only confirmed positive samples were consid-
ered anti-agalsidase alfa antibody positive and subjected to 
titer determination using the same ELISA format by serial 
twofold dilution until the signal fell below the screening cut 
point. Samples that were confirmed positive for the presence 
of anti-agalsidase alfa IgG, IgA, IgM, or IgE antibodies were 
further evaluated for the presence of neutralizing antibodies 
using an enzyme activity inhibition assay.
Efficacy evaluation
Similar to previous pediatric studies of agalsidase alfa 
ERT,13,16,17 the primary efficacy objective herein was to assess 
changes in the autonomic nervous system using HRV in chil-
dren with FD. Secondary efficacy objectives were to assess 
cardiac structure using left ventricular mass indexed to height 
(LVMI g/m2.7) and cardiac function via midwall fractional 
shortening (MFS), renal function (via estimated glomerular 
filtration rate [eGFR], assessing creatinine clearance from 
8-hour urine samples and calculating serum creatinine using 
Counahan–Barratt and Cockcroft–Gault equations), agalsi-
dase alfa pharmacodynamics (via plasma and urine levels of 
Gb
3
 at baseline and after ERT initiation), plus outcomes of 
clinical quality-of-life indices.
Autonomic function was evaluated via changes in the 
HRV parameters SDNN (standard deviation of all filtered 
RR intervals for the length of the analysis), r-MSSD (square 
root of the sum of squares of differences between adjacent 
filtered RR intervals over the length of the analysis), and 
pNN50 (percentage of differences between adjacent filtered 
RR intervals that is .50 ms for the whole analysis). Measure-
ment of SDNN describes both long-term (sympathetic) and 
short-term (parasympathetic) variability, reflecting overall 
autonomic nervous system activity in the heart, whereas 
r-MSSD and pNN50 both describe short-term variability, 
primarily reflecting parasympathetic influences on heart 
rate. Reduced parasympathetic stimulation of the heart has 
been reported in male pediatric patients with FD.13 Two-hour 
continuous ECG (Holter) monitoring13 was performed at 
rest and heart rate was assessed at a central laboratory under 
normal ranges estimated using a published correlation for-
mula for HRV and age.21
Cardiac structure and function were evaluated using 
echocardiography to determine LVMI and MFS (both 
calculated using published formulae);22 echocardiograms were 
analyzed in a central laboratory by a single, blinded reader. 
Normal reference values for LVMI were prospectively defined 
as ,51 g/m2.7 in males and ,48 g/m2.7 in females. These 
correspond to a conservative cutoff point that determines the 
presence of LVH in children and adolescents. However, this 
cutoff point also has established prognostic value in adults 
with hypertension,23 and is consistent with Fabry literature in 
both children and adults.24 Renal function was assessed using 
eGFR, calculated using the Counahan–Barratt equation, and 
urine protein and microalbumin values.
Finally, clinical quality-of-life outcomes were assessed 
using recommended methodologies for each of the follow-
ing instruments: the Brief Pain Inventory (BPI),25 Health 
Utilities Index (HUI2 and HUI3),26 and Childhood Health 
Questionnaire (CHQ-PF50; physical [PhS] and psychosocial 
scores [PsS]).27 The 10-point BPI is used to measure pain 
intensity and its interference in various functional domains. 
The HUI and CHQ assess quality-of-life using both self- and 
proxy-assessed forms. For the HUI, a score of 1.0 indicates 
best health and 0.0 worst health; for the CHQ, scoring 
ranges from 0 to 100 and is standardized so that increments 
above or below 50 (average) indicate change. For all three 
patient-reported outcomes, the forms were to be filled out 
before infusions and patients had to be older than 12 years 
to complete the forms by themselves.
Pharmacodynamic evaluation
Plasma and urinary Gb
3
 levels were measured at prespecified 
time points in blood samples from fasted patients and 8-hour 
urine samples, respectively. Liquid chromatography-tandem 
mass spectrometry, performed at a central laboratory using 
an AB Sciex API 5000 triple quadrupole mass spectrometer 
(Concord, Canada) coupled with a Waters Acquity UPLC 
system (Milford, MA, USA), was used to detect and monitor 
eleven different isoforms of Gb
3
, which were then combined 
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to calculate total values (method validated both in-house, 
Shire, and at the central laboratory).
statistical analysis
The safety population comprised all patients who enrolled 
in the study and received at least one dose of agalsidase alfa. 
Descriptive statistics were used to summarize demographic 
and baseline characteristics (also stratified by sex), treatment 
duration and exposure, efficacy endpoints, clinical laboratory 
measurements, and immunogenicity results. The effects of 
anti-agalsidase alfa antibodies on infusion-related AEs and 
on the clinical assessments above were analyzed by anti-
agalsidase alfa antibody status, where cases with at least one 
positive anti-agalsidase alfa antibody test during the study 
were considered positive, and cases with no positive test 
were considered negative.
Subgroup analyses by sex were performed for plasma and 
urinary Gb
3
, and HRV parameters and LVMI. Furthermore, 
changes in SDNN and LVMI over time were correlated 
in patients with baseline SDNN scores ,100 ms as a post 
hoc analysis to determine the possibility of a concurrent 
treatment effect, and Z-scores were calculated for the HRV 
parameters as an ad hoc analysis to compare normal ranges. 
SAS Software version 9.3 was used for all statistical analy-
ses of parameters reported herein (SAS Institute Inc., Cary, 
NC, USA).
The observed values and change from baseline for the 
BPI parameters, HUI2 and HUI3 scores, and CHQ-PF50 PhS 
and PsS were descriptively summarized.
Results
clinical and demographic characteristics
Fourteen patients comprised the safety population (Table 1) 
and all 14 (100%) received infusions of agalsidase alfa on all 
scheduled dates and completed the study. The median 
duration of agalsidase alfa exposure was 54.5 (range 54.0, 
59.0) weeks. Five (35.7%) of the patients were male, 
13 (92.9%) were white, and one (7.1%) was Hispanic. 
The median age overall at baseline was 11.8 (range 6.7, 
15.9) years: for males it was 10.2 (6.7, 14.4) years and for 
females 14.8 (10.1, 15.9) years. The median height and 
height Z-score at baseline were 150 (range 122, 167) cm 
and −0.04 (−1.10, 2.36), respectively. The median BMI and 
BMI Z-score at baseline were 20.8 (range 14.0, 33.3) and 
1.06 (−1.82, 3.14), respectively.
safety of agalsidase alfa
Clinical laboratory values, vital signs, and results from 
physical examinations and ECGs showed no change during 
the study. The overall mean change from baseline in height 
Z-score by week 55 was −0.18 (SD 0.31; median −0.13 
[range −0.76, 0.25]) and for BMI it was 0.06 (SD 0.63; 
Table 1 Demographic and baseline clinical characteristics
Characteristic, median (range) Male, N=5 Female, N=9
age, years 10.2 (6.7, 14.4) 14.8 (10.1, 15.9)
height, cm 132.0 (122.0, 167.0) 161.0 (146.0, 163.0)
Weight, kg 37.6 (22.0, 52.0) 60.3 (37.0, 86.0)
sDnn, ms 97.0 (43.0, 116.0) 108.0 (68.0, 172.0)
r-MssD, ms 63.0 (12.0, 91.0) 78.0 (27.0, 181.0)
pnn50, % 23.5 (0.5, 45.4) 41.1 (5.4, 69.2)
lVMi, g/m2.7 38.1 (20.2, 57.1) 35.2 (21.0, 44.2)
MFs, % 19.6 (12.4, 20.6) 19.5 (16.1, 22.2)
egFr, ml/min/1.73 cm2 113.5 (89.8, 141.9) 116.1 (98.9, 159.1)
Urine protein, mg/dl 4.3 (4.0, 6.7) 4.0 (4.0, 39.1)
Urine microalbumin, mg/dl 0.6 (0.3, 1.2) 0.7 (0.3, 6.9)
Plasma gb3, nmol/ml 24.2 (20.6, 48.0) 7.3 (4.6, 10.8)
Urine gb3, nmol/g creatinine 3,518.0 (1,530.0, 13,102.0) 338.0 (183.0, 648.0)
Characteristic, n (%)
lVh 1 (20) 0
Microalbuminuriaa 5 (100.0) 9 (100.0)
elevated plasma gb3
b 5 (100.0) 8 (88.9)
elevated urine gb3
c,d 5 (100.0) 9 (100.0)
ace inhibitor/arB usage 0 0
Notes: aspot urine microalbumin $0.3 mg/dl, data from Mehta a et al. and national Kidney Foundation i.32,33 bPlasma gb3 $5.26 nmol/ml. 
cUrine gb3 $30 nmol/g creatinine 
(plasma/urine gb3 reference ranges validated in-house, shire). 
dn=2 males missing baseline plasma gb3 values. pnn50 represents the percentage of differences between 
adjacent filtered RR intervals that are .50 ms for the whole analysis. r-MSSD represents the square root of the sum of squares of difference between adjacent filtered RR 
intervals over the length of the analysis. SDNN represents the standard deviation of all filtered RR intervals for the length of the analysis.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate; Gb3, globotriaosylceramide; lVh, 
left ventricular hypertrophy; lVMi, left ventricular mass index; MFs, midwall fractional shortening.
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median −0.09 [range −0.75, 1.50]), indicating stable growth 
during the treatment period.
adverse events
At least one treatment-emergent AE was reported by all 
14 patients (100%) during the study, most being mild (5/14; 
35.7%) or moderate (6/14; 42.9%) in severity. The most 
common treatment-emergent AEs (occurring in $25%) were 
pyrexia (n=6; 42.9%), cough, diarrhea, headache, nausea, pain 
in the extremity, upper respiratory tract infection, and vomiting 
(each n=4; 28.6%). Three patients (21.4%) experienced severe 
treatment-emergent AEs of mouth ulceration, tooth malforma-
tion, chest discomfort, alveolar ostitis, facial bone fracture, dys-
pnea, and angioedema (each reported by one patient only).
Eight patients (57.1%) experienced at least one infusion-
related AE. The most common were vomiting (n=4; 28.6%); 
nausea and dyspnea (each n=3; 21.4%); chest discomfort, 
chills, dizziness, and headache (each n=2; 14.3%). One patient 
had a likely allergic response with a number of severe infu-
sion-related reactions at week 49. These included angioedema, 
dyspnea, and chest tightness, all of which resolved following 
emergency treatment with 2.5 mg salbutamol inhaler and 
20 mg intravenous methylprednisolone. The infusion was 
later completed at a slower rate. Of note, this patient had a 
prior medical history of reactive airway disease, seasonal 
allergies, and eczema on the arms and thighs. At week 47, 
the same patient received a partial dose after the infusion 
was interrupted due to infusion-related AEs of nausea and 
vomiting. Both events resolved, but vein access could not be 
regained. Full doses were received for all subsequent infusions 
through week 55, although all were extended to over 1 hour. 
The patient was negative for IgE at all assessments.
Overall, infusion-related AEs were more likely to occur 
within the first 6 months of treatment with agalsidase alfa 
(21 patients with infusion-related AEs) than during the last 
6 months (ten patients). No deaths or serious AEs occurred 
during the study and there were no discontinuations due 
to an AE.
anti-agalsidase alfa antibodies
One patient tested positive for both IgG and neutralizing 
antibodies at weeks 49 and 55 (a summary of efficacy results 
for this patient is shown in Table 2). This patient reported 26 
mild or moderate infusion-related AEs and subsequently tested 
positive for anti-agalsidase alfa antibodies at week 49.
Efficacy and pharmacodynamic 
parameters
Baseline Z-scores indicated that the safety population had low 
to abnormal values of SDNN (Figure 1) and normal values 
of pNN50 and r-MSSD for age. Mean (SD) baseline values 
were: SDNN 103.46 (32.93) ms; pNN50 32.79% (20%); 
and r-MSSD 75.92 (45.75) ms. Median baseline values 
were: SDNN 100.00 (range 43.0, 172.0) ms; pNN50 26.74% 
Table 2 Summary of efficacy results for the only patient who tested positive for both IgG and neutralizing antibodies
Efficacy endpoint Baseline Change from baseline to
Week 13 Week 25 Week 37 Week 49 Week 55
HRV
sDnn (ms) 76.0 −1.0 −6.0 −12.0 – 17.0
r-MssD (ms) 63.0 −12.0 −15.0 −17.0 – 3.0
pnn50 (%) 26.7 −9.5 −10.8 −13.7 – 0.6
Cardiac structure
lVMi (g/m2.7) 48.2 −16.8 −2.2 −16.6 −12.4 −1.0
MFs (%) 15.9 4.0 1.5 3.8 2.8 3.9
Renal function
egFr (ml/min/1.73 m2) 104.9 0.0 28.4 3.4 33.8 6.0
Pharmacodynamics
Plasma gb3 (nmol/ml) 24.2 −10.7 −10.2 −10.5 −11.6 −6.9
Urinary gb3 (nmol/g creatinine) na
Clinical outcomes
BPi-worst pain 9 −9 −9 1 −5 −4
BPi-pain severity 4.75 −4.75 −4.75 −0.50 −2.75 −3.00
Overall hUi2 0.7 0.2 0.3 – 0.0 0.1
Overall hUi3 0.6 0.3 0.3 – 0.2 0.0
chQ-global health 30 0 30 30 0 30
Notes: pNN50 represents the percentage of differences between adjacent filtered RR intervals that are .50 ms for the whole analysis. r-MssD represents the square root 
of the sum of squares of difference between adjacent filtered RR intervals over the length of the analysis. SDNN represents the standard deviation of all filtered RR intervals 
for the length of the analysis.
Abbreviations: BPI, Brief Pain Inventory; CHQ, Children’s Health Questionnaire; eGFR, estimated glomerular filtration rate; Gb3, globotriaosylceramide; hrV, heart rate 
variability; hUi, health Utilities index; lVMi, left ventricular mass index; MFs, midwall fractional shortening; na, not available.
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(0.5, 69.2%); r-MSSD 67.00 (12.0, 181.0) ms. A subset of 
patients with mean baseline HRV values below the popula-
tion median was evaluated to further assess treatment effects. 
In seven patients with SDNN #100 ms, a slight but statisti-
cally nonsignificant improvement or no change in SDNN 
was observed over the course of the study (mean [SD] value 
at baseline: 81.6 [20.9] ms, mean change [95% confidence 
interval, CI] from baseline to week 55: 17.4 [2.9, 31.9] ms; 
median value at baseline: 88.0 [range 43.0, 100.0] ms, median 
change [95% CI] from baseline to week 55: 19.0 [−2.0, 45.0] 
ms). For the six patients who had baseline pNN50 #26.7%, 
no change was observed overall as the mean (SD) value at 
baseline was 16.1% (10.5%; median 20.4% [range 0.5%, 
26.2%]) and the mean change (95% CI) at week 55 was 7.7% 
(−6.5, 21.8%; median change [95% CI] 12.3% [−16.1%, 
19.7%]). Similarly, no difference overall was observed in 
seven patients who had baseline r-MSSD #67 ms as the 
mean (SD) at baseline was 44.6 (19.4) ms (median 48.0 [range 
12.0, 67.0] ms) and the mean change (95% CI) from baseline 
at week 55 was 27.0 (−21.3, 75.3) ms (median change [95% 
CI] 18.0 [−41.0, 124.0] ms).
When evaluated by sex, changes from baseline over 
the course of the study in all three HRV indices were not 
statistically significant overall (mean [95% CI] change from 
baseline by week 55 for SDNN: males 7.60 [−5.56, 20.76] 
ms, females 12.25 [−13.28, 37.78] ms; pNN50: males −1.72% 
[−14.03%, 10.59%], females −5.64% [−26.7%, 15.4%]; 
r-MSSD: males 3.00 [−41.67, 47.67] ms, females 0.50 
[−53.45, 54.45] ms. Median values for change from base-
line by week 55 for SDNN: males 2.00 [range −2.0, 21.0] 
ms, females 18.00 [−33.0, 51.0] ms; pNN50: males 0.11% 
[−16.1%, 11.3%], females −5.12% [−58.3%, 19.7%]; 
r-MSSD: males 1.00 [−41.0, 59.0] ms, females −0.50 [−98.0, 
124.0] ms). Males generally had numerically lower values 
of each HRV parameter than females.
For structural cardiac parameters, the mean [SD] values 
of LVMI were within the normal range (,51 g/m2.7 for 
males; ,48 g/m2.7 for females) at baseline for the majority 
of both males (38.75 [14.53] g/m2.7) and females (33.50 
[7.08] g/m2.7) and remained so throughout the study (mean 
[95% CI] change from baseline at week 55 −0.74 [−6.01, 
4.53] g/m2.7 for males and 0.66 [−4.77, 6.08] g/m2.7 for 
females). One male patient had LVH at baseline, with an 
LVMI value of 57.1 g/m2.7. At week 55 his LVMI value was 
59.9 g/m2.7; the interim values both increased and decreased, 
although all were below his baseline value (Figure 2). Median 
baseline LVMI was 38.07 (range 20.2, 57.1) g/m2.7 for males 
and 35.22 (21.0, 44.2) g/m2.7 for females; median change from 
baseline at week 55 was −1.00 (−6.3, 4.0) g/m2.7 for males 
and 3.23 (−8.5, 8.8) g/m2.7 for females.
There was a strong correlation between increases in 
SDNN and decreases in LVMI (r=−0.975; Figure 3) in 
patients with low to abnormal HRV (SDNN ,100 ms) and no 
LVH at baseline. However, a weaker correlation was found 
between these parameters for patients with SDNN $100 ms 
at baseline (r=0.229).
Figure 1 heart rate variability as assessed by sDnn: individual values at baseline and at 55 weeks.
Notes: (A) Observed values of sDnn (ms). (B) SDNN Z-scores. SDNN represents the standard deviation of all filtered RR intervals for the length of the analysis. The 
different colored shapes within the figure show individual patient data at baseline and 55 weeks.
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Figure 2 lVMi over time for the patient who had lVh at baseline.
Note: SDNN represents the standard deviation of all filtered RR intervals for the 
length of the analysis.
Abbreviations: lVh, left ventricular hypertrophy; lVMi, left ventricular mass index.
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MFS values at baseline were in agreement with MFS results 
previously reported in normal children28 (mean [SD] 17.75% 
[3.57%] for males and 19.11% [2.55%] for females; median 
19.60% [range 12.4%, 20.6%] for males and 19.52% [16.1%, 
22.2%] for females). Changes from baseline were small and 
remained within the normal range (overall mean change [95% 
CI] from baseline by week 55: −0.62% [−2.69%, 1.46%]; 
overall median change from baseline by week 55: −1.27 [range 
−6.1, 4.6]), as also found when evaluated by sex.
The mean (SD) eGFR at baseline was 117.5 (18.53) 
mL/min/1.73 m2 (median 115.7 [range 89.8, 159.1] mL/
min/1.73 m2), with a mean (95% CI) change from baseline 
at week 55 of 0.15 (−11.39, 11.70) mL/min/1.73 m2 (median 
0.72 [−27.5, 35.9] mL/min/1.73 m2). When examined by sex, 
slightly lower values for all renal function parameters were 
found in males compared with females (although the differ-
ences were not statistically significant). The mean (SD) eGFR 
at baseline was 115.3 (19.96) mL/min/1.73 m2 for males and 
118.7 (18.81) mL/min/1.73 m2 for females. Median baseline 
values were 113.5 (range 89.8, 141.9) mL/min/1.73 m2 for 
males and 116.1 (98.9, 159.1) mL/min/1.73 m2 for females. 
Mean eGFR values did not change over the course of the 
study; for males, the mean (95% CI) change from baseline 
by week 55 was 4.26 (−21.20, 29.71) mL/min/1.73 m2 and 
for females it was −2.41 (−18.39, 13.57) mL/min/1.73 m2 
(Figure 4). The median change from baseline by week 55 
was 3.44 (range −24.1, 33.8) mL/min/1.73 m2 for males and 
0.31 (−27.5, 35.9) mL/min/1.73 m2 for females.
The results for urine protein and microalbumin show no 
difference over the course of the study. Overall mean (SD) 
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Figure 3 correlation between change from baseline to week 55 in sDnn and lVMi in patients with baseline sDnn ,100 ms.
Notes: *r= Pearson correlation coefficient. SDNN represents the standard deviation of all filtered RR intervals for the length of the analysis.
Abbreviation: lVMi, left ventricular mass index.
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Figure 4 Mean (se) change from baseline in egFr.
Note: The safety population comprises all enrolled patients who received at least one dose of agalsidase alfa.
Abbreviations: eGFR, estimated glomerular filtration rate; SE, standard error; SP, safety population.
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baseline values and mean (95% CI) changes from baseline 
by week 55 were: urine protein, 7.43 (9.26) and −1.79 
(−5.95, 2.37) mg/dL, and urine microalbumin, 1.16 (1.70) 
and 0.61 (−0.53, 1.75) mg/dL, respectively. Overall median 
baseline values and changes from baseline at week 55 were 
4.05 (range 4.0, 39.1) and 0.00 (−26.2, 3.5) mg/dL for urine 
protein, and 0.65 (0.3, 6.9) and 0.00 (−0.7, 7.1) mg/dL for 
urine microalbumin, respectively.
The mean plasma Gb
3
 level in males showed a consider-
able decrease from baseline by week 13, with a steady reduc-
tion maintained over the remainder of the study (Figure 5); 
this reduction was lower in females, who had lower baseline 
levels, and occurred from week 25 onward. Mean (SD) 
plasma Gb
3
 levels at baseline were 28.20 (11.36) nmol/mL 
in males and 7.34 (1.92) nmol/mL in females (median values 
were 24.2 [range 20.6, 48.0] nmol/mL in males and 7.3 [4.6, 
10.8] nmol/mL in females). Mean (95% CI) changes from base-
line by week 55 were −15.18 (−25.9, −4.5) nmol/mL and −0.46 
(−1.39, 0.47) nmol/mL, respectively (median changes from 
baseline were −12.9 [range −29.8, −6.9] nmol/mL in males 
and −0.9 [−2.2, 1.4] nmol/mL in females).
Mean (SD) urinary Gb
3
 levels at baseline were 6,050.0 
(6,187.57) nmol/g creatinine in males and 350.11 
(155.56) nmol/g creatinine in females; they decreased from 
baseline at each time point in both (mean change [95% CI] 
from baseline by week 55: −4,952.0 [−22,067.84, 12,163.84] 
and −220.33 [−329.78, −110.89] nmol/g creatinine, respec-
tively). Median baseline values and change from baseline by 
week 55 were 3,518.0 (range 1,530.0, 13,102.0) and −3,160.0 
(−12,561.0, 865.0) nmol/g creatinine in males, and 338.0 
(183.0, 648.0) and −206.0 (−501.0, −28.0) nmol/g creatinine 
in females.
Among the patient-reported outcomes for quality-of-life, 
the BPI variable “worst pain last week”, primarily used to 
assess changes in neuropathic pain, showed a reduction in 
pain with a median (range) change from baseline at week 55 
of −3.0 (−7, 0) points. The other patient-reported outcome 
assessments, BPI, HUI, and CHQ, showed little variation 
over the course of the 55-week study. Overall health-related 
quality-of-life as assessed by the HUI2 showed a median 
(range) change from baseline at week 55 of 0.06 (−0.1, 0.4) 
points, and for the HUI3 it was 0.05 (−0.2, 0.6) points. The 
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Figure 5 Mean plasma gb3 over time for the overall population and by sex.
Notes: (A) Observed values (nmol/ml). (B) change from baseline.
Abbreviation: gb3, globotriaosylceramide.
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CHQ-PF50 raw scores were essentially unchanged from 
baseline. The median (range) change was −0.6 (−12.9, 31.4) 
for CHQ-PF50 PhS and 2.16 (−10.7, 16.6) for PsS.
Discussion
While safety and efficacy of ERT with agalsidase alfa have 
previously been studied in children with FD,14,15 the pres-
ent study evaluated agalsidase alfa in ERT-naïve children 
after a change in the manufacturing process of the drug. 
In agreement with earlier studies,14,15 agalsidase alfa was 
well tolerated overall, with high rates of study completion 
and treatment adherence (100% infusion attendance rate). 
Of note, the majority of patients in this study were females, 
who typically show later symptom onset than males.7
In general, treatment-emergent AEs were consistent 
with the known safety profile of agalsidase alfa and typi-
cal FD sequelae. Similar to previous pediatric studies, no 
life-threatening treatment-emergent AEs or deaths were 
reported,14,15 and the majority of patients reported treatment-
emergent AEs that were mild or moderate in intensity. All 
treatment-emergent AEs resolved and no new safety concerns 
were identified.
Despite protocol differences between studies in the 
reporting of infusion-related AEs (unlike in previous studies, 
in this study, all adverse drug reactions that occurred within 
12 hours were considered infusion-related AEs), the overall 
type and rate of adverse drug reactions reported by patients 
in this study are similar to those found in earlier studies.14,15 
The incidence of infusion-related AEs decreased after the 
first 6 months of ERT with agalsidase alfa.
The overall incidence of IgG antibodies is similar to 
previous experience,14,15 and in the majority, the formation 
of anti-agalsidase alfa antibodies had no apparent short-
term impact on the safety or efficacy of agalsidase alfa. The 
male patient who tested positive for both IgG and neutral-
izing antibodies had stable efficacy parameters throughout 
the study.
An impaired HRV is considered to be an early sign of 
FD, earlier than that of increasing LVM, and can be present 
by adolescence in both sexes despite the lack of major organ 
dysfunction.2 Previous HRV analyses in children with FD 
revealed that boys, but not girls, had significantly reduced 
HRV, reflecting a reduction in parasympathetic stimulation 
of the heart.13 In boys, HRV indices, particularly SDNN, 
were shown to improve after treatment with agalsidase alfa 
for 6 months.16 In long-term studies, there was a sustained 
improvement in time-domain indices of HRV in boys on 
agalsidase alfa ERT over a period of 4 years.15,17 In the cur-
rent study, most of the HRV indices were normal at baseline. 
This study showed no deterioration in cardiac function over 
the 55 weeks of treatment, including children with low or 
abnormal HRV (SDNN) but without evidence of LVH. 
The fact that a reduction in LVM strongly correlated with an 
increase in SDNN in patients with low to abnormal SDNN 
at baseline indicates that early intervention could be benefi-
cial in preventing LVH. This correlation was not shown in 
patients with normal SDNN. A longer study of agalsidase 
alfa treatment in such patients would be needed to evaluate 
whether improvements in cardiac function could occur, but it 
could be possible that starting agalsidase alfa ERT in child-
hood, before major organ dysfunction has occurred, can help 
prevent the longer-term complications of FD.
Biopsy data in patients with FD show that glycosphin-
golipid deposits are present in cardiac myocytes and con-
duction tissue.29 Therefore, the possibility of a concurrent 
treatment effect in patients with advanced conduction 
abnormalities was examined. A subset of patients with the 
lowest SDNN at baseline was selected; in these patients, 
LVMI was generally within the normal range (all except 
for one patient, whose LVMI values varied throughout and 
are difficult to interpret) while SDNN was low or abnormal 
for age, as assessed by Z-scores. The change in SDNN for 
patients with low or abnormal SDNN was plotted against 
the change in LVMI. The selected patients had a baseline 
SDNN that was lower than the median of the study popula-
tion (ie, SDNN ,100 ms). The cutoff point of 100 ms also 
represents an important prognostic cutoff point for HRV.30,31 
In fact, there is general consensus that HRV is considered 
normal (confers good prognosis) if SDNN .100 ms. The 
corollary is not true, as there is no clear consensus about 
which SDNN values are associated with a poor prognosis. A 
strong correlation was observed between increasing SDNN 
and decreasing LVMI after treatment began in patients 
with abnormal baseline SDNN. For completeness, changes 
in SDNN and LVMI were also plotted for patients with 
preserved HRV, as defined by an SDNN $100 ms (or at or 
above the median of this study). As expected, in the latter 
group, no correlation was observed. However, almost all 
patients had normal baseline values of LVMI and MFS,28 
and it was not possible to assess whether a similar correlation 
would hold true in patients with more advanced disease, such 
as patients with low or abnormal HRV and LVH. Overall, 
these results indicate a potential stabilization or trend toward 
improvement in cardiac function when ERT is started as 
soon as children show low HRV and before they develop 
LVH, and are consistent with previous findings that showed 
increases in HRV and stable cardiac function and structure 
over time.15,16
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Renal parameters showed no change during treatment 
in the majority of patients. Changes in levels of urinary or 
plasma Gb
3
 have not been correlated with efficacy of ERT; 
however, they can demonstrate the pharmacological effect 
of ERT. In this study, a desired pharmacological effect of 
treatment with agalsidase alfa was reflected by a general 
decrease in plasma and urinary Gb
3
, more so in males than 
females, as found previously.14 The female patients in this 
study had notably lower baseline plasma Gb
3
 levels compared 
with males.
The patient-reported quality-of-life outcome measures 
generally showed average to good results at baseline and did 
not change throughout the duration of the study. A benefit of 
ERT with agalsidase alfa was reflected by a reduction from 
baseline in the BPI “worst pain last week” subscale.
Some limitations of this current study include the 
following. It was primarily designed to assess safety and 
thus was an open-label clinical trial with no placebo control 
for comparison. The number of patients in the total safety 
group and thus subgroup analyses was small; only descriptive 
statistics were used. Furthermore, patients with FD in this 
study were young, with no overt clinical manifestations of the 
disease to reverse. Finally, for this study, comparisons with 
similar studies on agalsidase alfa only focus on general trends 
because of the differences in protocol design,14,15 and com-
parisons with natural history cohorts were not possible due 
to the lack of data on the natural course of FD in children.
In addition to assessing the safety and efficacy of agal-
sidase alfa and despite the small sample size, this study rep-
resents a valuable addition to the body of evidence of ERT 
treatment effects in children, since very few such studies 
have been conducted in children to date.
Conclusion
The safety profile of agalsidase alfa in this study was 
consistent with that found in previous studies on children 
with FD. Agalsidase alfa was generally well tolerated in 
both males and females and no apparent short-term impact 
on safety or efficacy from IgG or neutralizing antibodies 
was found. Treatment with agalsidase alfa may slow the 
progression of cardiac, renal, and autonomic nervous system 
parameters. Long-term studies are needed to confirm whether 
later-onset complications of FD could be prevented with 
timely agalsidase alfa therapy in the pediatric age group.
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